CompletedNCT02604693
Exposure in Epigenetic Regulation of Immune Response in Chronic Beryllium Disease (CBD)
Studying Chronic beryllium disease
Last synced from ClinicalTrials.gov
ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing dataKey facts
- Sponsor
- National Jewish Health
- Principal Investigator
- Lisa Maier, MDNational Jewish Health
- Intervention
- Nothing(other)
- Enrollment
- 148 enrolled
- Eligibility
- 18-80 years · All sexes
- Timeline
- 2014 – 2020
Study locations (1)
- National Jewish Health, Denver, Colorado, United States
Primary source
Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.
Open NCT02604693 on ClinicalTrials.gov